Filana Therapeutics (FLNA) Research & Development (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Research & Development of $3.3 million for Q2 2026, down 35.44% year-over-year from $5.1 million in Q2 2025, and down 27.31% quarter-over-quarter from $4.5 million in Q1 2026.
Filana Therapeutics (FLNA) Research & Development (2010 - 2026) Analysis & Trends
Filana Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $3.3 million for Q2 2026.
- In Q2 2026, Research & Development fell 35.44% year-over-year to $3.3 million; the TTM figure through Jun 2026 stood at $15.7 million (down 72.53% YoY), while the FY2025 annual figure was $26.6 million, down 61.82% from the prior year.
- Research & Development for Q2 2026 stood at $3.3 million, down from $4.5 million in the prior quarter.
- The five-year high for Research & Development was $25.0 million in Q2 2023, with the low at $3.3 million in Q2 2026.
- The 5-year median for Research & Development is $16.6 million (2022), against an average of $14.5 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 489.4% in 2022, then plunged 81.23% in 2025.
- Filana Therapeutics' Research & Development stood at $17.7 million in 2022, then gained by 6.11% to $18.7 million in 2023, then grew by 9.6% to $20.5 million in 2024, then slumped by 81.23% to $3.9 million in 2025, then fell by 14.27% to $3.3 million in 2026.
- Business Quant data shows FLNA's Research & Development at $3.3 million in Q2 2026, $4.5 million in Q1 2026, and $3.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Filana Therapeutics | 45.29 Mn | 45.29 Mn | - | 3.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.30 Mn |
| Mar 31, 2026 | 4.54 Mn |
| Dec 31, 2025 | 3.85 Mn |
| Sep 30, 2025 | 3.96 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Mar 31, 2025 | 13.67 Mn |
| Dec 31, 2024 | 20.53 Mn |
| Sep 30, 2024 | 17.68 Mn |
| Jun 30, 2024 | 15.20 Mn |
| Mar 31, 2024 | 16.23 Mn |
| Dec 31, 2023 | 18.73 Mn |
| Sep 30, 2023 | 23.60 Mn |
| Jun 30, 2023 | 24.97 Mn |
| Mar 31, 2023 | 22.12 Mn |
| Dec 31, 2022 | 17.65 Mn |
| Sep 30, 2022 | 18.53 Mn |
| Jun 30, 2022 | 16.95 Mn |
| Mar 31, 2022 | 14.91 Mn |
| Dec 31, 2021 | 10.34 Mn |
| Sep 30, 2021 | 8.04 Mn |